Alterity Therapeutics Files 6-K on EGM Results
Ticker: PRNAF · Form: 6-K · Filed: Apr 12, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, agm-results, registration-statement
TL;DR
Alterity Therapeutics filed a 6-K on April 12th detailing EGM results, incorporated into S-8 and F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on April 12, 2024, to report the results of its Extraordinary General Meeting. This filing is incorporated by reference into several of the company's existing registration statements on Form S-8 and Form F-3.
Why It Matters
This filing provides an update on shareholder decisions made at the Extraordinary General Meeting, which could impact the company's strategic direction and future operations.
Risk Assessment
Risk Level: low — The filing is a routine report of meeting results and incorporation by reference, not indicating new financial distress or significant operational changes.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- April 12, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated registration statement
- Form F-3 (document) — Incorporated registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the results of Alterity Therapeutics Limited's Extraordinary General Meeting held in April 2024.
Which registration statements is this 6-K filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 12, 2024.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address of Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics Limited file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics Limited indicates that it files annual reports under Form 20-F.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-04-12 08:00:03
Filing Documents
- ea0203771-6k_alterity.htm (6-K) — 14KB
- ea020377101ex99-1_alterity.htm (EX-99.1) — 4KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- ex99-1_002.jpg (GRAPHIC) — 203KB
- 0001213900-24-032316.txt ( ) — 310KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Results of Extraordinary General Meeting 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: April 12 , 2024 2